WallStSmart

Amphastar P (AMPH)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1921% more annual revenue ($14.56B vs $720.53M). AMPH leads profitability with a 11.0% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 0.14. VTRS earns a higher WallStSmart Score of 50/100 (C-).

AMPH

Buy

50

out of 100

Grade: C-

Growth: 4.7Profit: 6.0Value: 5.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.23

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMPHUndervalued (+9.6%)

Margin of Safety

+9.6%

Fair Value

$31.64

Current Price

$21.78

$9.86 discount

UndervaluedFair: $31.64Overvalued

Intrinsic value data unavailable for VTRS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMPH2 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

P/E RatioValuation
12.7x8/10

Attractively priced relative to earnings

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

AMPH4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

Market CapQuality
$927.72M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.772/10

Expensive relative to growth rate

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AMPH

The strongest argument for AMPH centers on Price/Book, P/E Ratio.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : AMPH

The primary concerns for AMPH are Revenue Growth, Market Cap, Piotroski F-Score.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

AMPH profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

AMPH carries more volatility with a beta of 0.90 — expect wider price swings.

VTRS is growing revenue faster at 8.1% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Bottom Line

AMPH scores higher overall (50/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphastar P

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?